EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Recent Patents and Emerging Therapeutics in the Treatment of Allergic Conjunctivitis

Gyan P Mishra, Viral Tamboli, Jwala Jwala, Ashim K Mitra

Recent Patents on Inflammation & Allergy Drug Discovery · 01.01.2011 · 5 (1) · 26-36

DOI: 10.2174/187221311794474883 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Recent Patents on Inflammation & Allergy Drug Discovery, erschienen am 01.01.2011. Verfasst von Gyan P Mishra und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, MO 64108-2718, USA. Die Arbeit wurde bisher 66-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NEI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ocular allergy is an inflammatory response of the conjunctival mucosa that also affects the cornea and eyelids. Allergic conjunctivitis includes seasonal allergic conjunctivitis (SAC), perennial allergic conjunctivitis (PAC), vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC) and giant papillary conjunctivitis (GPC). In general, allergic conditions involve mast cell degranulation that leads to release of inflammatory mediators and activation of enzymatic cascades generating pro-inflammatory mediators. In chronic ocular inflammatory disorders associated with mast cell activation such as VKC and AKC constant inflammatory response is observed due to predominance of inflammatory mediators such as eosinophils and Th2-generated cytokines. Antihistamines, mast-cell stabilizers, nonsteroidal anti-inflammatory agents, corticosteroids and immunomodulatory agents are commonly indicated for the treatment of acute and chronic allergic conjunctivitis. In recent years newer drug molecules have been introduced in the treatment of allergic conjunctivitis. This article reviews recent patents and emerging therapeutics in the treatment of allergic conjunctivitis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenal Cortex HormonesAnti-Inflammatory Agents, Non-SteroidalConjunctivitis, AllergicHistamine AntagonistsHumansImmunologic FactorsMast CellsPatents as TopicT-Lymphocytes

Substanzen

Adrenal Cortex HormonesAnti-Inflammatory Agents, Non-SteroidalHistamine AntagonistsImmunologic Factors

Autor:innen und Institutionen

  • Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, MO 64108-2718, USA.

Förderung

  • NEI NIH HHS

Zitieren

APA

Mishra, G. P., Tamboli, V., Jwala, J., & Mitra, A. K. (2011). Recent Patents and Emerging Therapeutics in the Treatment of Allergic Conjunctivitis. Recent Patents on Inflammation & Allergy Drug Discovery, 5(1), 26-36. https://doi.org/10.2174/187221311794474883

Vancouver

Mishra GP, Tamboli V, Jwala J, Mitra AK. Recent Patents and Emerging Therapeutics in the Treatment of Allergic Conjunctivitis. Recent Patents on Inflammation & Allergy Drug Discovery. 2011;5(1):26-36. doi:10.2174/187221311794474883

BibTeX
@article{Mishra2011,
  author = {Mishra, Gyan P and Tamboli, Viral and Jwala, Jwala and Mitra, Ashim K},
  title = {Recent Patents and Emerging Therapeutics in the Treatment of Allergic Conjunctivitis},
  journal = {Recent Patents on Inflammation & Allergy Drug Discovery},
  year = {2011},
  volume = {5},
  number = {1},
  pages = {26--36},
  doi = {10.2174/187221311794474883}
}
Kostenlos starten →